Liver Health Management
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Learn more
FibroScan® GO
The state-of-the-art non-invasive solution, affordable to all.
Powered by LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.
Supported by 6 270+ peer reviewed publications and 250+ guidelines.
An ideal solution for point-of-care use
Pay-per-exam solution.
A full ecosystem of solutions,including service coverage
and support.
Centralized data management and user-friendly interface.
A small and compact device for easy integration at a busy practice
Enhanced care for your patients
Simple, fast assessment of your patients’ liver health.
Innovative, next generation technology, offers simplified exams on all morphologies.
Immediate results for informative and straightforward provider/patient consultations.
Identify, assess and monitor patients at risk for liver disease right in your office
A cloud-based solution offering you Everyday support
Automate the transfer of FibroScan® results to the LHM platform to help you make data-driven decisions.
Access historical patient data and generate reports easily shared with patients and referring physicians.
Enhance examinations with FibroScan® based Scores and interpretation tools.
Monitor and manage your patients’ liver disease with patient history and clinical care pathway tools right in the LHM platform.
Guided VCTE™ : the next generation VCTE™ technology
The new Guided VCTE™ technology offers intuitive features for faster examinations and simplified scanning.
Tried & Trusted
FibroScan® is perfect for use in a primary care setting, it is portable and gives patients an instant result enabling them to leave with the result.
Fibroscan® is key to providing a Community service, which is part of the wider pathway to increase early detection and timely intervention and management of patients with and at-risk of liver disease.
FibroScan® as an interventional therapy helps primary care physicians and nurse specialists engage patients by demonstrating the results and outcomes as a value change.
Peace of mind with pro-active and dedicated support
Assists you with onsite installation and training.
Includes maintenance, calibration of probes and software updates.
Easy access to continuous training and users community with Echosens Academy.
A state-of-the-art FibroScan®
Quickly and easily assess liver stiffness using LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.1,2,3
FibroScan® 230 is a class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and is manufactured by Echosens™. FibroScan® 230 is intended to provide Liver stiffness measurements at a shear wave frequency of 50 Hz and Liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz. FibroScan® 230 is a non-invasive device intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® device may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis.
FibroScan® device is used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
All personal and health data generated by the FibroScan® GO solution is managed in compliance with local data privacy and GDPR regulations. Data located on Echosens Cloud is managed by an ISO 27001 certified organization.
1. Wong VW, et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478.
2. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
3. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.
Already a FibroScan GO® user?
To access the FibroScan® 230 user guides, connect to the LHM platform (Echosens Cloud)
Learning Center > FibroScan® GO
Going further in the management of liver disease
FibroScan® Probes
Optimize measurement accuracy on all patient morphologies
Learn more
FibroScan® by echosens
The non-invasive gold standard solution for comprehensive management of liver health
Learn more
EASL Clinical Practice Guidelines
Non-invasive evaluation of liver disease severity and prognosis
Learn more
